Xtant Medical Stock Price, News & Analysis

Xtant Medical Holdings, focused on surgical solutions for spinal disorders, reported a 42% revenue increase to $15.0 million for Q2 2021 compared to the previous year. The gross margin improved to 63.5% from 62.2%. The net loss shrank to $0.7 million or $0.01 per share, significantly better than the $2.5 million loss in Q2 2020. The company closed a $20 million debt refinancing and reported a Non-GAAP Adjusted EBITDA of $0.9 million. Xtant's expansion in sales force and distribution aims to enhance future growth.

Xtant Medical Holdings, Inc. (XTNT) will release its financial results for Q2 2021 on August 5, 2021, before the market opens. The conference call will be hosted by CEO Sean Browne and CFO Greg Jensen at 9:00 AM ET, providing insights into the company’s performance in the spinal disorder market. Investors can access the call via dial-in or webcast, with a replay available on their website.

Xtant Medical Holdings, Inc. (NYSE American: XTNT) will have its CEO Sean Browne present at the Canaccord Musculoskeletal Conference on May 20, 2021, at 3:00 PM ET. The presentation focuses on innovations in spinal surgery solutions. Investors can access a live webcast on the company's website. A replay will be available for 90 days post-event. Xtant Medical specializes in spinal implant systems, offering comprehensive orthobiologics for complex spine procedures.

Xtant Medical Holdings, Inc. (XTNT) reported Q1 2021 results, with revenue of $12.5 million, a decrease from $14.8 million in Q1 2020, mainly due to COVID-19 impacts. Operating expenses fell to $8.1 million from $11.0 million as a result of lower sales and wages. The company incurred a net loss of $29,000, a significant improvement from $2.5 million in the prior period. Non-GAAP Adjusted EBITDA rose to $0.8 million from $0.3 million. Xtant raised $18.4 million from a private placement and secured $20 million in debt refinancing to bolster growth initiatives.

Xtant Medical Holdings, Inc. (NYSE American: XTNT) has filed a universal shelf registration statement on Form S-3 with the SEC, allowing the company to offer and sell various securities up to $150 million over three years. This filing is aimed at enhancing capital market access for financing growth initiatives. Additionally, it permits OrbiMed Advisors, LLC to sell up to 18,218,374 shares of XTNT common stock. The company currently has no specific plans for issuing securities under this registration, and proceeds from any stock sales will not benefit Xtant directly.

Xtant Medical Holdings, Inc. (NYSE American: XTNT) has entered into new credit agreements with MidCap Financial Trust, which include a $12 million secured term loan at 7% interest and an $8 million secured revolving credit facility at 4.5% interest. These agreements replace the existing loan from OrbiMed, fully repaying that debt. The new financing is aimed at enhancing the company's balance sheet and supporting strategic growth initiatives.

Xtant Medical Holdings, Inc. (NYSE American: XTNT) will release its Q1 2021 financial results on May 11, 2021, before market open. A conference call, led by CEO Sean Browne and CFO Greg Jensen, will take place at 9:00 AM ET on the same day to discuss the results. Interested parties can join the call using the provided dial-in numbers or register for the webcast. The company specializes in surgical solutions for spinal disorders, including orthobiologics and spinal implant systems.

Xtant Medical Holdings, Inc. (NYSE American: XTNT) announced that it is not aware of any undisclosed corporate developments accounting for the recent surge in its share price and trading volume. The company focuses on surgical solutions for spinal disorders, offering a range of orthobiologics and spinal implant systems. Their commitment to integrity and customer service remains a priority as they navigate the market fluctuations.

Xtant Medical Holdings, Inc. (NYSE American: XTNT) has successfully closed a $20 million private placement with a healthcare-focused institutional investor. The deal involved the sale of 8,888,890 common shares and warrants for 6,666,668 shares, at a price of $2.25 each. Net proceeds after fees are approximately $18.4 million, intended for working capital and other corporate purposes. The warrants are exercisable at the same price, expiring in five years. Sean Browne, President and CEO, expressed that this funding will support growth initiatives and enhance shareholder value.